
Opinion|Videos|December 25, 2024
Exploring Second-Line Treatments for PBC
Panelists discuss how some patients with primary biliary cholangitis (PBC) have an inadequate response to ursodeoxycholic acid and require second-line treatments, with options including obeticholic acid, seladelpar, and elafibranor, which improve bile acid homeostasis and reduce inflammation.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How often do patients require second-line treatments for PBC, and what agents are available for second-line management?
- How do the mechanisms of action differ between seladelpar, elafibranor, and obeticholic acid?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Lerodalcibep for Hypercholesterolemia and Heterozygous Familial Hypercholesterolemia
2
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
Once-Weekly Retatrutide Reduces Weight and Knee Pain in Patients With Obesity and Osteoarthritis
5
















































































































































































































